1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Sanofi Has One Hemophilia Winner On It Hands – But Fitusiran’s Fate Remains Unclear

Efanesoctocog Alfa Filed Last Month

 
• By Andrew McConaghie

Sanofi is hoping to have two paradigm-changing hemophilia drugs on the market by 2025 – but one of these, fitusiran, must first prove its safety and efficacy at a lower dose.

Sanofi_Berlin
Sanofi could be a major player in hemophilia within a few years - but will face competition from Roche's Hemlibra and gene therapies. • Source: Shutterstock

Having compelling Phase III data for one new hemophilia therapy would usually enough cause for celebration, but Sanofi has just unveiled strong results for two potential blockbuster candidates, efanesoctocog alfa and fitusiran.

The company unveiled the studies at the International Society on Thrombosis and Haemostasis (ISTH) in London on 10 July, and they could help make

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

 
• By Sushmita Panda

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval

 
• By Kevin Grogan

The small interference RNA therapeutic can be used by patients regardless of inhibitor status.

With Phase III Success, PharmaEssentia To Seek Besremi Label Expansion (Update)

 
• By Joseph Haas

Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.